General description
Microtubule-associated protein tau (UniProt P29172; also known as Neurofibrillary tangle protein, Paired helical filament-tau, PHF-tau) is encoded by the MAPT (also known as TAU) gene (Gene ID 281296) in bovine species. Extracellular plaque deposits composed of amyloid-β and intracellular neurofibrillary tangles (NFTs) composed of truncated and hyperphosphorylated tau are two neuropathological hallmarks of Alzheimer′s disease (AD). Tau pathology (tauopathy) can cause toxicity when the brain is devoid of amyloid plaques, and tangle pathology correlates better with clinical dementia than amyloid pathology. Abnormal processing of tau by hyperphosphorylation and proteolytic truncation contribute to the toxicity of tau. Tau is known to be cleaved by various proteases, including caspases, calpains, cathepsins, thrombin, and puromycin-sensitive aminopeptidase, as well as the lysosomal cysteine proteinase asparagine endopeptidase (AEP). MAPK, GSK-3, and Cdk-5 are three known kinases that target various tau phosphorylation sites. Tau also undergoes other types of posttranslational modifications, including glycosylation, ubiquitination, glycation, polyamination, nitration, and lysine methylation, which are believed to be important for its non-pathological functions, including polymerization and stabilization of microtubules.
Specificity
Clone PC1C6 was originally designated as clone Tau-1. Clone PC1C6 (Tau-1) was initially thought to specifically target a form of tau present in axons by immunohistochemical staining of rat brain tissue (Binder, L.I. et al. (1985). J. Cell Biol. 101(4):1371-1378), later studies revealed that its immunoreactivity and therefore tissue staining pattern depends on the state of tau phosphorylation. Specifically, clone Tau-1 displayed diminished immunoreactivity toward Tau when phosphorylated in its epitope region. Sample dephosphorylation by alkaline phosphatase treatment enhanced the immunoreactivity of this clone in Western blotting and immunohistochemistry applications (Papasozomenos, S.C., and Binder, L.I. (1987) Cell Motil. Cytoskeleton. 8(3):210-216; Szendrei, G.I., et al. (1993). J. Neurosci. Res. 34(2):243-249); Billingsley, M.L., and Kincaid, R.L. (1997). Biochem. J. 323(Pt 3):577-591; Dotti, C.G., et al. (1987). Neuroscience. 23(1):121-130).
Immunogen
Epitope: Internal (C-terminal half).
Purified denatured bovine microtubule associated proteins.
Application
Immunofluorescence Analysis: A 1:300 dilution from a representative lot detected Tau in rat brain tissue.
The unconjugated antibody (Cat. No. MAB3420) is shown to be suitable also for Western blotting and immunohistochemistry applications.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases
This Anti-Tau Antibody, clone PC1C6, Alexa Fluor™ 555 Conjugate is validated for use in Immunofluorescence, Immunocytochemistry for the detection of Tau.
Quality
Evaluated by Immunofluorescence in mouse brain tissue.
Immunofluorescence Analysis: A 1:150 dilution of this antibody detected Tau in mouse brain tissue.
Target description
~79 kDa observed.
Physical form
Protein A purified
Purified mouse monoclonal IgG2a antibody conjugate in PBS with 15 mg/mL BSA and 0.1 % sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Other Notes
Concentration: Please refer to lot specific datasheet.
Legal Information
ALEXA FLUOR is a trademark of Life Technologies
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.